• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Daily aspirin may benefit some patients without existing cardiovascular disease

byNiki WintersandDeepti Shroff Karhade
October 7, 2019
in Cardiology, Chronic Disease, Emergency, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The benefit of daily aspirin varied dramatically depending on whether one cardiovascular disease event was equivalent to one or two bleeding events

2. Subgroups that tended to benefit more from aspirin treatment included patients with cardiovascular disease risk factors such as hyperlipidemia, hypertension, diabetes, smokers) and those with lower bleeding risk factors.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Aspirin reduces the risk of cardiovascular disease (CVD) in at-risk patients while increasing the risk of bleeding, but it is unclear if aspirin benefits outweigh the risks in patients without known CVD. This study found that when a CVD event was considered equivalent to 2 major bleeding events, net benefits of aspirin increased to 21% of women and 41% of men. Patients with more CVD risk factors (including hyperlipidemia, hypertension, diabetes, smokers) and those with lower bleeding risk factors benefited more from aspirin treatment. Despite the significance of these results, one limitation of this study was the generalizability of findings given that the study took place in a New Zealand primary care setting. Further, because the study design incorporated hemorrhagic stroke as an outcome for CVD and bleeding risk scores, the true proportion of patients who experienced a net benefit may be higher than reported. Future studies should further compare the threshold of CVD risk above which aspirin is beneficial to the threshold of bleeding risk above which aspirin is harmful. To help make these decisions at present, it is important for both the clinician and patient to discuss the risks and benefits of aspirin to decide what is best for them.

Click to read the study in Annals of Internal Medicine

Click to read an accompanying editorial in Annals of Internal Medicine

Relevant Reading: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force

RELATED REPORTS

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

In-Depth [systematic review and meta-analysis]: This New Zealand study was a systematic review of 245,028 New Zealand residents from January 2012 to December 2016 without established CVD, including ages 30 to 79 years (43.6% women). Researchers conducted a risk-benefit analysis of aspirin use in patients without CVD. The net effect of aspirin was calculated by subtracting the number of prevented CVD events from the number of major bleeds likely to be caused over 5 years. CVD and bleeding risk were calculated using models validated in PREDICT cohort data, a web-based program integrated with New Zealand’s electronic primary care practice systems. Patients were excluded if they were outside of the age range, had a history of CVD, CHF, atrial fibrillation, CKD, diabetes, intracranial bleeding, or those receiving an anti-thrombotic agent in the past 6 months. When a hospitalization or death from a CVD event and major bleed are considered equivalent, the net benefit from aspirin ranged from 0.0% to 28.5% in women and 0.1% to 50% among men (using the upper and lower limits of 95% CIs). Greater net benefits were seen in subgroups that were older, current smokers, had diabetes, or were receiving blood pressure or lipid lowering medication. If 1 CVD event was considered equivalent to 2 major bleeds, the net benefit from aspirin increased to 0.1% to 60% in women and 1.9% to 77.9% among men, using the upper and lower limits of 95% CIs and not point estimates. Greater net benefits were seen in patients with a lower baseline bleeding risk and non-current smokers.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirinbleeding eventscardiovascular diseasestroke
Previous Post

Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout

Next Post

Quick Take: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

RelatedReports

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]
Cardiology

Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism

August 11, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
Patient Basics: Atherosclerosis
Chronic Disease

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

August 5, 2022
#VisualAbstract: Nonoperative management of uncomplicated acute appendicitis comparable to appendectomy but leads to increased length of stay and disease recurrence
StudyGraphics

#VisualAbstract: Thrombectomy alone is inferior to thrombectomy plus alteplase for acute ischemic stroke

August 5, 2022
Next Post
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

Quick Take: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

General anesthesia exposure in infants not linked to impaired cognitive development

Early revascularization improves survival in patients with ischemia demonstrated on positron emission tomography perfusion imaging

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dulaglutide improves glycemic control for youth with type 2 diabetes
  • Cinpanemab therapy does not prevent Parkinson’s disease progression
  • Criteria for low-dose computed tomography lung cancer screening omit a high risk population of smokers
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.